Skip to main content

How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug

The company's stock soared Monday on results from a late-stage clinical trial pairing with a major cancer immunotherapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.